Clinical Trial Finder

Inclusion Criteria:

• - >=18 years old.

• - Performance status ECOG 0-2.

• - Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.

• - Patient must be planned for or receiving standard of care chemoimmunotherapy.

• - Patient must have received no more than 3 cycles by time of study enrollment.

• - Able and indicated according to investigator to receive thoracic radiotherapy.

• - 18 years old.

• - Diagnosis of solid tumor malignancy with MRI-defined brain metastasis lesions (1-5 lesions allowed) within 60 days of registration.

• - Each brain metastasis lesion enrolled must be 2 - 5 cm, except brainstem lesions which may be 1.5 - 5cm in size.

Exclusion Criteria:

• - Prior whole brain Radiotherapy.

• - Prior surgical resection or focal radiotherapy of a target brain metastasis.

Cohort-Specific Rationale.COHORT A (ES-SCLC Personalized ultrahypofractionated stereotactic ablative radiotherapy (PULSAR) Thoracic Tumor): Chemoimmunotherapy with 4-6 cycles of platinum/etoposide and PD-L1 (Programmed Death-Ligand 1 protein) inhibition has become the standard systemic therapy for extensive stage small cell lung cancer (ES-SCLC), based on modest but significant OS (overall survival) benefits seen with the addition of either atezolizumab or durvalumab to chemotherapy in the IMpower133 and CASPIAN trials, respectively. However, outcomes remain poor with median OS of only 12.3 months. Notably, consolidative thoracic RT (radiotherapy) was not allowed either trial. This contrasts with prior signal for potential benefit for addition of thoracic RT to standard chemotherapy in ES-SCLC in the CREST trial, though this was not duplicated the RTOG 0937. Encouraging preliminary safety data has been published for addition of hypofractionated thoracic RT to single agent PD-1 inhibition after response to induction chemotherapy (6% grade 3 toxicity), but toxicities with doublet immune checkpoint blockade (ipilimumab/nivolumab) and RT showed a nearly 20% rate of high grade AEs (adverse events). This has led to an ongoing cooperative study (NRG LU007) seeking to define the impact of consolidative thoracic RT given with atezolizumab following induction chemotherapy. In the interim, while use of thoracic RT consolidation in ES-SCLC remains supported as a standard of care by guidelines, its implementation is variable. Particularly important open question involve timing for synergy/additivity with immune checkpoint blockade and cytotoxic therapy, minimization of target size for safety, and tailoring of dose according to patient need given significant competing risks for extra-thoracic progression and tolerance. In seeking to address this, this study notes that small cell lung cancer generally shrinks rapidly with each cycle of chemoimmunotherapy. Delivering a "pulse" of RT to the thoracic disease immediately prior to cycles 2-6 of chemoimmunotherapy may result in faster tumor response and reduction of overall treatment target size. Moreover, prolongation of time between doses enables observation of response, which would allow investigators to withhold further RT dose in those unlikely to benefit due to extra-thoracic progression or exceptional early response of thoracic disease. COHORT B (Brain metastasis PULSAR): Brain metastases from solid tumors affect nearly 30% of patients who die of cancer and present an increasing challenge for management as patients live longer with improved systemic therapies. Treatment often includes radiotherapy, increasingly delivered as stereotactic radiosurgery (SRS) to spare normal brain. For larger lesions or those near sensitive areas, fractionated stereotactic radiation therapy (FSRT) delivered in up to 5 treatments is used to reduce swelling and late injury. Prolongation of the duration between fSRT treatments from days to weeks further has enabled adjustments of the treatment target to tumor size changes over treatment, further reducing healthy brain exposure without sacrifice in tumor control (7). UT Southwestern has expanded upon this modified fSRT approach with PULSAR. Based upon observed kinetics of response, the predominant PULSAR approach has been to deliver treatments in two "pulses" given as 3 fractions every other day, 3-4 week break, and then 2 final fractions every other day. In the initial experience (n=109 treated lesions), PULSAR demonstrated favorable efficacy and tolerability in treating brain metastases (2-year 90% local control and <10% grade 3 toxicity), when compared to historical fSRT reports especially for larger >=2cm lesions. PULSAR for brain metastases thus shows high potential to address larger tumors and to individualize RT dose/intensity, especially in the setting of increasing numbers of central nervous system (CNS)-active systemic agents. In particular, with longer patient survivals, there remains a critical need to reduce the risk of toxicity and edema by de-escalating dose in addition to target size. The best 'biomarker' for such de-escalation appears to be early radiographic response, with published work strongly correlating a >=20% lesion volume reduction by 3-months to improved local control. Notably, such reductions are commonly seen in time for decision making in the PULSAR approach, with the collected data previously showing a median 38% reduction in larger tumors (>=2cm) during treatment. Specifically, ~50% of patients achieve a 25% reduction by pulse 2. In this cohort, the study will assess whether a more conservative >=25% tumor volume at interim imaging of PULSAR can be used to omit the second "pulse" for "responders," while retaining high control rates.

Arms

Interventions